Affymetrix buys Panomics for $73m
This article was originally published in Clinica
Molecular diagnostics specialist Affymetrix has acquired Panomics, a developer of low- to mid-plex assays, in a bid to capitalise on the high-growth validation and routine-testing market segments. Privately-held Panomics will be bought for $73m in cash and the transaction is expected to close at the end of 2008. Fremont, California-based Panomics' assays currently run on an installed base of over 5,600 instruments. The assays, used for genetic, protein and cellular analysis, are designed for ease of use – they work on a wide range of sample types and do not require nucleic acid extraction or amplification, according to Affymetrix. The addition of Panomics' products will enable its acquirer to offer a more complete customer workflow, "beginning with whole-genome Affymetrix microarray studies and then focusing on genes and proteins of interest with the Panomics products", said Santa Clara, California-based Affymetrix.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.